Literature DB >> 11270590

Sympathetic nervous system and chronic renal failure.

R Boero1, A Pignataro, M Ferro, F Quarello.   

Abstract

The aim of this work was to review evidence on the role of the sympathetic nervous system (SNS) in chronic renal failure (CRF). Three main points are discussed: 1) SNS and pathogenesis of arterial hypertension; 2) SNS and cardiovascular risk; 3) implication of SNS in arterial hypotension during hemodialysis. Several lines of evidence indicate the presence of a sympathetic hyperactivity in CRF, and its relationship with arterial hypertension. It is suggested that diseased kidneys send afferent nervous signals to central integrative sympathetic nuclei, thus contributing to the development and maintenance of arterial hypertension. The elimination of these impulses with nephrectomy could explain the concomitant reduction of blood pressure. Several experiments confirmed this hypothesis. Regarding SNS and cardiovascular risk, some data suggest that reduced heart rate variability identifies an increased risk for both all causes and sudden death, independently from other recognized risk factors. Symptomatic hypotension is a common problem during hemodialysis treatment, occurring in approximately 20-30% of all hemodialysis sessions and is accompanied by acute withdrawal of sympathetic activity, vasodilation and relative bradicardia. This reflex is thought to be evoked by vigorous contraction of a progressively empty left ventricle, activating cardiac mechanoceptors. This inhibits cardiovascular centers through vagal afferents, and overrides the stimulation by baroreceptor deactivation. Alternative explanations include cerebral ischemia and increased production of nitric oxide, which inhibit central sympathetic activity. It is hoped that therapies aimed at modulating sympathetic nerve activity in patients with CRF will ameliorate their prognosis and quality of life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270590     DOI: 10.1081/ceh-100001198

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  6 in total

1.  Reduction in synaptic GABA release contributes to target-selective elevation of PVN neuronal activity in rats with myocardial infarction.

Authors:  Tae Hee Han; Kiho Lee; Jin Bong Park; Dongchoon Ahn; Jae-Hyeong Park; Dae-Yong Kim; Javier E Stern; So Yeong Lee; Pan Dong Ryu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-17       Impact factor: 3.619

2.  Enhanced astroglial GABA uptake attenuates tonic GABAA inhibition of the presympathetic hypothalamic paraventricular nucleus neurons in heart failure.

Authors:  Sudip Pandit; Ji Yoon Jo; Sang Ung Lee; Young Jae Lee; So Yeong Lee; Pan Dong Ryu; Jung Un Lee; Hyun-Woo Kim; Byeong Hwa Jeon; Jin Bong Park
Journal:  J Neurophysiol       Date:  2015-06-10       Impact factor: 2.714

3.  Reduced heart rate volatility: an early predictor of death in trauma patients.

Authors:  Eric L Grogan; John A Morris; Patrick R Norris; Daniel J France; Asli Ozdas; Renée A Stiles; Paul A Harris; Benoit M Dawant; Theodore Speroff
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

4.  Autonomic dysfunction in uremia assessed by heart rate variability.

Authors:  Kálmán Tory; Zsuzsanna Süveges; Erzsébet Horváth; Eva Bokor; Péter Sallay; Klára Berta; Attila Szabó; Tivadar Tulassay; György S Reusz
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

5.  Influence of combined hypertension and renal failure on functional alpha(1)-adrenoceptor subtypes in the rat kidney.

Authors:  M A Hye Khan; M A Sattar; N A Abdullah; E J Johns
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

Review 6.  Targeting autonomic nervous system as a biomarker of well-ageing in the prevention of stroke.

Authors:  Jean-Claude Barthelemy; Vincent Pichot; David Hupin; Mathieu Berger; Sébastien Celle; Lytissia Mouhli; Magnus Bäck; Jean-René Lacour; Frederic Roche
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.